Prokidney Corp. shares surge 661.12% intraday after reporting positive Phase 2 trial results for REGEN-007.

Prokidney Corp. surged 661.12% intraday, following the release of positive Phase 2 REGEN-007 trial results, showing significant improvements in eGFR decline rates for both patient groups, with no serious adverse events related to rilparencel. The company plans to hold an FDA Type B meeting in the summer of 2025 to confirm eGFR slope as an alternative endpoint for the Phase 3 PROACT 1 study, aiming to accelerate approval. Prokidney is a late-stage clinical cell therapy company focused on chronic kidney disease, with its primary product candidate, rilparencel, being an autologous cell therapy designed to preserve kidney function.